Current Report Filing (8-k)
08 November 2022 - 08:01AM
Edgar (US Regulatory)
false 0001488039 0001488039 2022-11-07
2022-11-07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 7,
2022
Atossa Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| |
|
|
|
|
|
Delaware
|
|
001-35610
|
|
26-4753208
|
| |
|
|
|
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
| |
|
|
| |
|
|
|
107 Spring Street
Seattle, Washington
|
|
98104
|
| |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(206) 325-6086
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
Securities registered pursuance to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.18 par value
|
ATOS
|
The Nasdaq Capital Market
|
Item 2.02. Results of Operations and Financial
Condition.
On November 7, 2022, Atossa Therapeutics, Inc. (the “Company”)
issued a press release announcing the quarter ended September 30,
2022 financial results and a Company update. A copy of the
press release is attached as Exhibit 99.1 to this current report
and is incorporated herein by reference.
The information in Items 2.02, and 9.01 of this report,
including Exhibit 99.1 attached hereto, shall not be deemed to
be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section or Sections 11 and 12(a)(2) of
the Securities Act of 1933, as amended. The information contained
herein and in the accompanying exhibit shall not be incorporated by
reference into any filing with the U.S. Securities and Exchange
Commission made by the Company, whether made before or after the
date hereof, regardless of any general incorporation language in
such filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
| |
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
| |
|
|
|
104
|
|
Cover page Interactive Data File (embedded within the Inline XBRL
document)
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
|
Date: November 7, 2022
|
Atossa Therapeutics, Inc.
|
|
| |
By:
|
/s/ Kyle Guse
|
|
| |
|
Kyle Guse
|
|
| |
|
Chief Financial Officer, General Counsel and Secretary
|
|
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Feb 2023 to Mar 2023
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2022 to Mar 2023
